Snail-mediated regulation of reactive oxygen species in ARCaP human prostate cancer cells

Petrina Barnett1, Rebecca S Arnold, Roman Mezencev

  • 1Center for Cancer Research and Therapeutic Development, Department of Biological Sciences, Clark Atlanta University, Atlanta, GA 30314, USA.

Insights

Snail transcription factor drives prostate cancer aggressiveness by increasing reactive oxygen species (ROS) and promoting epithelial-mesenchymal transition (EMT). Targeting Snail may offer a therapeutic strategy to combat tumor progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Reactive oxygen species (ROS) are implicated in cancer progression and epithelial-mesenchymal transition (EMT).
  • Snail transcription factor is a known inducer of EMT, contributing to tumor aggressiveness.

Purpose of the Study:

  • To investigate the molecular mechanisms by which Snail promotes tumor aggressiveness in prostate cancer.
  • To elucidate the role of ROS in Snail-mediated EMT.

Main Methods:

  • Utilized ARCaP prostate cancer cell line to create a Snail overexpression EMT model.
  • Measured ROS levels (superoxide, hydrogen peroxide) in vitro and in vivo.
  • Assessed gene expression of oxidative stress-responsive genes using Real Time PCR.
  • Investigated the effects of ROS scavenger N-acetyl cysteine and MEK inhibitor UO126 on EMT.

Main Results:

  • Snail overexpression decreased E-cadherin and increased vimentin, confirming EMT induction.
  • Snail-expressing cells exhibited elevated ROS levels.
  • Oxidative stress-responsive genes, including aldehyde oxidase I, were upregulated by Snail.
  • N-acetyl cysteine partially reversed EMT, while UO126 treatment more effectively restored epithelial morphology and E-cadherin expression.

Conclusions:

  • Snail transcription factor regulates oxidative stress enzymes, increasing ROS-mediated EMT.
  • ERK activation plays a role in ROS-mediated EMT induced by Snail.
  • Snail represents a potential therapeutic target for preventing prostate cancer progression.